| Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study S Modi, H Park, RK Murthy, H Iwata, K Tamura, J Tsurutani, ... Journal of Clinical Oncology 38 (17), 1887, 2020 | 582 | 2020 |
| Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer EA Perez, VJ Suman, NE Davidson, JR Gralow, PA Kaufman, ... Journal of Clinical Oncology 29 (34), 4491, 2011 | 320 | 2011 |
| Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature A Dispenzieri, A Moreno-Aspitia, GA Suarez, MQ Lacy, G Colon-Otero, ... Blood 104 (10), 3400-3407, 2004 | 275 | 2004 |
| Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line … HS Rugo, WT Barry, A Moreno-Aspitia, AP Lyss, C Cirrincione, E Leung, ... Journal of Clinical Oncology 33 (21), 2361, 2015 | 228 | 2015 |
| Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials R Bradley, J Braybrooke, R Gray, R Hills, Z Liu, R Peto, L Davies, ... The Lancet Oncology 22 (8), 1139-1150, 2021 | 181 | 2021 |
| Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic … A Moreno-Aspitia, RF Morton, DW Hillman, WL Lingle, KM Rowland Jr, ... Journal of Clinical Oncology 27 (1), 11, 2009 | 170 | 2009 |
| DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine J Yu, BO Qin, AM Moyer, S Nowsheen, T Liu, S Qin, Y Zhuang, D Liu, ... The Journal of clinical investigation 128 (6), 2376-2388, 2018 | 165 | 2018 |
| Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2–positive primary breast cancer: analysis from the ALTTO … A Sonnenblick, D Agbor-Tarh, I Bradbury, S Di Cosimo, HA Azim Jr, ... Journal of Clinical Oncology 35 (13), 1421, 2017 | 143 | 2017 |
| Treatment options for breast cancer resistant to anthracycline and taxane A Moreno-Aspitia, EA Perez Mayo Clinic Proceedings 84 (6), 533-545, 2009 | 131 | 2009 |
| Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer EA Perez, T Patel, A Moreno-Aspitia Breast cancer research and treatment 121, 261-271, 2010 | 125 | 2010 |
| Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine … EA Perez, A Awada, J O'Shaughnessy, HS Rugo, C Twelves, SA Im, ... The Lancet Oncology 16 (15), 1556-1568, 2015 | 98 | 2015 |
| Accrual of older patients with breast cancer to alliance systemic therapy trials over time: protocol A151527 RA Freedman, JC Foster, DK Seisler, JM Lafky, HB Muss, HJ Cohen, ... Journal of Clinical Oncology 35 (4), 421, 2017 | 84 | 2017 |
| Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer A Moreno-Aspitia, EA Perez Future Medicine Ltd 1 (6), 755-762, 2005 | 84 | 2005 |
| Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients M Lambertini, C Campbell, J Bines, LA Korde, M Izquierdo, D Fumagalli, ... JNCI: Journal of the National Cancer Institute 111 (1), 86-94, 2019 | 83 | 2019 |
| Current strategies for the prevention of breast cancer P Advani, A Moreno-Aspitia Breast Cancer: Targets and Therapy, 59-71, 2014 | 81 | 2014 |
| Adjuvant therapy of triple negative breast cancer EA Perez, A Moreno-Aspitia, E Aubrey Thompson, CA Andorfer Breast cancer research and treatment 120, 285-291, 2010 | 79 | 2010 |
| Tumor sequencing and patient-derived xenografts in the neoadjuvant treatment of breast cancer MP Goetz, KR Kalari, VJ Suman, AM Moyer, J Yu, DW Visscher, ... JNCI: Journal of the National Cancer Institute 109 (7), djw306, 2017 | 72 | 2017 |
| Anthracycline-and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends A Moreno-Aspitia, EA Perez Clinical therapeutics 31 (8), 1619-1640, 2009 | 72 | 2009 |
| Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines JA Crozier, A Swaika, A Moreno-Aspitia World journal of clinical oncology 5 (3), 529, 2014 | 71 | 2014 |
| Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG oncology/NSABP B-31 S Chumsri, Z Li, DJ Serie, A Mashadi-Hossein, G Colon-Otero, N Song, ... Journal of Clinical Oncology 37 (35), 3425, 2019 | 70 | 2019 |
